3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
May 11-15, 2026 – Boston, MA
🔬 Where Cell and Gene Therapy Moves Forward
Veristat is pleased to attend the ASGCT Annual Meeting, where leaders across cell and gene therapy come together to share progress, tackle challenges, and shape what comes next. As programs advance through early-phase development, the stakes are high. Scientific complexity, evolving regulatory expectations, and the need for clear, defensible data all converge at this stage.
Our team looks forward to connecting with sponsors and innovators to discuss how Veristat supports cell and gene therapy programs with integrated regulatory, clinical, and biostatistical expertise. The focus is simple: make development capital count and enable faster, more confident decisions as therapies move closer to patients.
👥 Meet with us at the ASGCT Annual Meeting
Connect with Erin Gaffney, our Senior Business Development Director, to explore how Veristat’s scientific leadership and focused capabilities can help advance your clinical and regulatory milestones.
📅 Schedule a meeting in advance
Complete the form on this page to reserve time with our team. We welcome the opportunity to learn about your upcoming programs and explore how Veristat can support your development strategy.
💡 Our Expertise
Whether you're launching a first-in-human study or navigating complex regulatory pathways, Veristat delivers integrated expertise and personalized support across the development lifecycle:
-
Full-Service Clinical Development Solutions
-
Clinical Operations Excellence
- Global Regulatory Strategy & Submissions
Let's shape the future of clinical research, together.
Schedule A Meeting
Meet with us at the ASGCT Annual Meeting
Boston | May 11-15
3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...